top of page

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Score

  • Jan 22, 2019
  • 1 min read

Updated: Sep 21, 2021

Prostate Cancer Genomic-risk Differences Between African-American and White Men Across Gleason Scores


Brandon A Mahal, Mohammed Alshalalfa, Daniel E Spratt, Elai Davicioni, Shuang G Zhao, Felix Y Feng, Timothy R Rebbeck, Paul L Nguyen, Franklin W Huang


African-American men have poorer prostate cancer-specific outcomes compared with white men [1]. Emerging evidence suggests that racial disparities in advanced stage or higher-grade disease may be predominantly accounted for by social factors and healthcare access [2,3]. In contrast, there is growing evidence to support the hypothesis that disparities in low-grade Gleason 6 disease may be in part driven by underlying tumor differences [3,4]. Although low-grade (Gleason 6) disease is considered prognostically favorable, it is associated with a diverse genomic landscape that can sometimes include aggressive genomic features [5].



Please contact us if you are having difficulty accessing the full PDF of this or any MADCaP publication.



Recent Posts

See All

Comments


© Copyright 2016-2022 

Dana-Farber Cancer Institute.

Use of MADCaP is subject to our terms of use and our privacy policy.

MADCaP Network
Dana-Farber Cancer Institute
450 Brookline Avenue
Boston, MA 02215

Supported by Dana-Farber Cancer Institute

MADCaP is grant-funded by the National Cancer Institute

NCI_Stacked_COLOR.png
img-logo-2x-new.png
bottom of page